Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491150 | 0.73 | HTT (0.56) | HTTPARP1 | |
| SCHEMBL5778409 | 0.73 | HTT (0.56) | HTTPARP1 | |
| SCHEMBL30440549 | 0.70 | LMNA (0.31) | — | |
| SCHEMBL9937148 | 0.70 | LMNA (0.31) | — | |
| Hydrochloric Acid SCHEMBL25274167 | 0.69 | LMNA (0.31) | — | |
| SCHEMBL5778738 | 0.69 | HTT (0.50) | HTT | |
| SCHEMBL18347744 | 0.67 | MYC (0.41) | HTTPARP1 | |
| SCHEMBL10248414 | 0.62 | HTT (0.61) | HTT | |
| SCHEMBL26262626 | 0.62 | MAT2A (0.30) | — | |
| SCHEMBL25802549 | 0.62 | AAK1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| EP-3268373-B1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-107406462-B | Tricyclic DLK inhibitors and uses thereof | 豪夫迈·罗氏有限公司 | 2020-11-10 | — | — | CN | disclosed |
| US-10131675-B2 | Tricyclic DLK inhibitors and uses thereof | GENENTECH, INC. (US) | 2018-11-20 | — | — | US | disclosed |
| EP-3268373-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. Hoffmann-La Roche AG (CH) | 2018-01-17 | — | — | EP | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | GENENTECH, INC. (US) | 2017-12-28 | — | — | US | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
| WO-2016142310-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2016-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10131675-B2 | Tricyclic DLK inhibitors and uses thereof | NLK, DCLK2, DLK1 | AR 4080/4885HTT 353/4885PARP1 3830/4885 |
| US-20170369510-A1 | TRICYCLIC DLK INHIBITORS AND USES THEREOF | NLK, DCLK2, DLK1 | AR 4080/4885HTT 353/4885PARP1 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.